Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Opens Asia Pacific Headquarters In Singapore

This article was originally published in PharmAsia News

Executive Summary

Merck has opened an Asia Pacific headquarters in Singapore, the firm announced Aug. 21

You may also be interested in...



Merck's Licensing & External Research Director Jennifer Hu On Choosing Partners In China: An Interview With PharmAsia News

Big pharma's rush into emerging markets is bringing more R&D to these markets, and as one of the key emerging markets China has attracted most multinational companies to set their R&D and licensing footprint here. Jennifer Hu, Merck's director of licensing and external research, recently shared her thoughts with PharmAsia News' Shanghai bureau about Merck's partnering and licensing strategy in China.

Merck's Licensing & External Research Director Jennifer Hu On Choosing Partners In China: An Interview With PharmAsia News

Big pharma's rush into emerging markets is bringing more R&D to these markets, and as one of the key emerging markets China has attracted most multinational companies to set their R&D and licensing footprint here. Jennifer Hu, Merck's director of licensing and external research, recently shared her thoughts with PharmAsia News' Shanghai bureau about Merck's partnering and licensing strategy in China.

Asia Set To Become New Center Of Pharma: PricewaterhouseCoopers Report

China and India seen as countries with the highest growth potential.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel